Medtronic receives FDA clearance for LigaSure RAS
Medtronic (NYSE:MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument, expanding the available tools for its Hugo robotic-assisted surgery system in the United States.
Medtronic (NYSE:MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument, expanding the available tools for its Hugo robotic-assisted surgery system in the United States.
AEVEX (NYSE:AVEX) was selected for a contract valued at up to $92.2 million over three years to support the Department of War’s Test Resource Management Center SkyRange program.
LuxExperience (NYSE:LUXE) reported fourth-quarter fiscal 2026 net sales of €653.6 million, up 6.1% year-over-year on a reported basis and 7.6% excluding foreign exchange effects.
Starbucks (NASDAQ:SBUX) is considering selling a majority stake in its Japan business in a potential transaction that could value the operation at approximately $3 billion, according to people familiar with the matter.
SK Hynix (NASDAQ:SKHY) is in discussions with Intel (NASDAQ:INTC) about potential arrangements to manufacture memory chips in the United States, according to people familiar with the talks.
McCormick & Company (NYSE:MKC) faces a review by Britain’s competition regulator over its planned acquisition of the majority of Unilever’s foods business.
BitMart has launched a user portal as advisers review its finances and withdrawal arrangements.
Oil prices declined on Wednesday after a two-day rally, with Brent crude futures falling $1.22 to $107.53 per barrel and U.S. West Texas Intermediate futures dropping $1.64 to $104.19 per barrel following an unexpected increase in U.S. crude inventories.
Brookfield (NYSE:BAM) agreed through its flagship private equity strategy to acquire 100% of Reliance Worldwide Corporation for US$3.38 per share in an all-cash transaction with an enterprise value of approximately US$2.8 billion.
Ispire Technology I (NASDAQ:ISPR) reported an adjusted quarterly loss of $0.24 per share for the quarter ended June 2026, compared with the Zacks Consensus Estimate of a $0.02 loss per share.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy